Related Experiment Video
Updated: May 16, 2026
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Quantitative metabolomics identifies prognostic biomarkers associated with NSCLC after chemoradiotherapy
Leirui Yuan1, Linfang Wu2,3, Mingmin Qian1
1Key Laboratory of Mass Spectrometry Imaging and Metabolomics (National Ethnic Affairs Commission), Center for Imaging and Systems Biology, College of Life and Environmental Sciences, Minzu University of China, Beijing, 100081, China. chenyanhua@muc.edu.cn.
Abstract:
Introduction: The high mortality of non-small cell lung cancer (NSCLC) is influenced by pre-treatment individual variability, yet reliable prognostic biomarkers are lacking, hindering precision therapy. Objectives: This study aimed to identify plasma metabolite biomarkers for predicting prognosis in stage III NSCLC patients using a targeted quantitative metabolomics approach. Methods: Plasma samples from 113 stage III NSCLC patients with long-term follow-up and 57 healthy controls were analyzed via LC-MS/MS-based targeted metabolomics. Patients were stratified into favorable and poor prognosis groups based on three-year survival. Differential metabolites were identified, and their association with overall survival was evaluated using Kaplan-Meier analysis. Results: Several metabolites differed between NSCLC patients and controls. Survival analysis revealed that elevated glutathione (GSH) levels were significantly associated with improved overall survival (p = 0.0013). Conversely, higher levels of glutamylglutamine (Glu-Gln) (p = 0.0117) and lysophosphatidylcholine 18:3 (LPC 18:3) (p = 0.0119) were correlated with poorer overall survival. Conclusion: This study identifies GSH and LPC 18:3 as promising prognostic biomarkers for stage III NSCLC. These findings provide new insights into patient stratification and the development of personalized treatment strategies.
